RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
PROCOPIO G
Collezione ASL Cuneo 2
Items : 36
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.
2024
ASL Cuneo 2
AO Ordine Mauriziano
Rescigno P; Fornarini G; Buti S; Rebuzzi SE; Vignani F; Cavo A; Signori A; Banna GL; Tudini M; Malgeri A; Nole F; Prati G; Morelli F; Messina M; Di Napoli M; Atzori F; Prati V; Soraru M; Panni S; Mollica V; Pipitone S; Ricotta R; Fratino L; Catalano F; Milella M; Procopio G; Naglieri E; Masini C; Zucal PA; et alii...
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. in ESMO open / ESMO Open. 2024 Jul;9(7):103484. doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.
2024
AOU Alessandria
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Asti
De Giorgi U; Santini D; Bertoldo F; Tucci M; Valsecchi AA; Procopio G; Berruti A; Di Maio M; Pantano F; Cursano MC;
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? in European urology oncology / Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
2024
ASL Cuneo 2
AOU Novara
Porta C; Battelli N; Bracarda S; Sorgentoni G; Monteiro FSM; Mollica V; Rizzo A; Zabalza IO; Bimbatti D; Soares A; Bisonni R; Rebuzzi SE; Roviello G; Incorvaia L; Morelli F; Santini D; Vau N; Bhuva D; Küronya Z; Mosca A; Landmesser J; Milella M; Messina C; Bassanelli M; Ortega C; Grillone F; Procopio G; Sunela K; Caffo O; et alii...
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.
2024
ASL Cuneo 2
Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.
2024
ASL Cuneo 2
AO Ordine Mauriziano
Chiellino S; Galli L; Banna GL; Fornarini G; Rescigno P; Cremante M; Damassi A; Catalano F; Roviello G; Cavo A; Lipari H; Vignani F; Prati G; Spada M; Nolè F; Morelli F; Di Napoli M; Caffo O; Malgeri A; Atzori F; Prati V; Tudini M; Sorarù M; Mollica V; Ricotta R; Baldessari C; Procopio G; Milella M; Fratino L; et alii...
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney in Clinical Genitourinary Cancer
2024
ASL Cuneo 2
Giudice GC; Maruzzo M; Verzoni E; Procopio G; Bimbatti D; Sepe P; Maines F; Grillone F; Cavo A; Santoni M; Cordua N; Pecoraro G; Prati V; Napoli MD; Ollari E; Caruso G; Simoni N; Campobasso D; Buti S;
2024
ASL Cuneo 2
ASL Asti
Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
2024
ASL Cuneo 2
ASL Asti
Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.
2023
ASL Cuneo 2
AO Ordine Mauriziano
Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G; Di Napoli M; Malgeri A; Cavo A; Vignani F; Nolè F; Prati G; Atzori F; Morelli F; Caffo O; Prati V; Mollica V; Tudini M; Fratino L; Sorarù M; Ricotta R; Pipitone S; Catalano F; Chiellino S; Milella M; Procopio G; Fornarini G; Zucali PA; Buti S; et alii...
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep
2023
ASL Cuneo 2
AOU Novara
Santoni M; Porta C; Bellmunt J; Battelli N; Sorgentoni G; Landmesser J; Rizzo A; Mollica V; Zabalza IO; Zgura A; Incorvaia L; Ansari J; Pinto A; Soares A; Nunes F; Maluf F; Morelli F; Mosca A; Zakopoulou R; Bisonni R; Manneh R; Santini D; Inman E; Herchenhorn D; Kanesvaran R; Caitano M; Milella M; Kopecky J; Martignetti A; et alii...
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). in International journal of molecular sciences / Int J Mol Sci. 2023 Jan 6;24(2):1096. doi: 10.3390/ijms24021096.
2023
ASL Cuneo 2
Santini D; Verzoni E; Procopio G; Fratino L; Santoni M; Prati V; Cavo A; Mennitto A; Maiorano BA; Malgeri A; Ermacora P; Vitale MG; Di Napoli M; Iacovelli R; De Giorgi U; Bersanelli M; Carella C; Pierantoni F; Maruzzo M; Buti S; Stellato M;
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. in ESMO open / ESMO Open. 2023 Aug;8(4):101598. doi: 10.1016/j.esmoop.2023.101598. Epub 2023 Jul 17.
2023
AO Cuneo
ASL Cuneo 2
Porta C; Rizzo M; Trerotoli P; Funaioli C; Ricotta R; Santoni M; Ortega C; Giron Berrios JR; Facchini G; Incorvaia L; Zanardi E; Stellato M; Fornarini G; Galli L; Atzori F; Passarelli A; Bersanelli M; Procopio G; Bracarda S; Caffo O; Rudà R; Maiorano BA; Massari F; Internò V;
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7.
2023
AO Cuneo
ASL Cuneo 2
AOU Novara
Grande E; Santoni M; Buti S; Battelli N; Sorgentoni G; Pierantoni F; Monteiro FS; Rebuzzi SE; Roviello G; Soares A; Zabalza IO; Rizzo A; Bisonni R; Morelli F; Incorvaia L; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Messina C; Merler S; Landmesser J; Grillone F; Ortega C; Sunela K; Ansari J; Atzori F; Bassanelli M; et alii...
2023
ASL Cuneo 2
Giannatempo P; Bottiglieri A; Guadalupi V; Marandino L; Raggi D; Stellato M; Rametta A; Baciarello G; Sepe P; Claps M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Cattaneo L; Verzoni E; Ortega C; Procopio G; Necchi A;
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.
2022
ASL Cuneo 2
AO Ordine Mauriziano
Roviello G; Rescigno P; Cavo A; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Santini D; Cortellini A; Prati V; Soto Parra HJ; Mollica V; Sorarù M; Santoni M; Panni S; Ricotta R; Pipitone S; Fratino L; Buti S; Procopio G; Milella M; Boccardo F; Fantinel E; Naglieri E; Galli L; et alii...
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. in Journal of clinical pathology / J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3.
2022
ASL Cuneo 2
ASL Cuneo 1
ASL Asti
Antonelli A; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Alongi F; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Rebuzzi SE; Fornarini G; Vellone VG; Bersanelli M; Buti S; Zivi A; et alii...
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. in Journal of personalized medicine / J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.
2022
ASL Asti
AOU Città della Salute di Torino
ASL Cuneo 1
ASL Cuneo 2
Antonelli A; Porta C; Delahunt B; Giannarini G; Signori A; Banna GL; Rescigno P; Obispo MAL; Bortolus R; Perris R; Scaltriti M; Moch H; Fassan M; Dei Tos AP; Colecchia M; Franco R; Zito-Marino F; Aberasturi Plata Y; Galuppini F; Sbaraglia M; Bollito E; Cossarizza A; Massari F; Salvioni R; Rizzo M; Conti G; Lapini A; Colombo P; Patriarca C; et alii...
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.
2022
ASL Cuneo 2
AO Ordine Mauriziano
Buti S; Fornarini G; Banna GL; Porta C; Llaja Obispo MA; Roviello G; Cavo A; Vignani F; Nolè F; Caffo O; Messina M; Morelli F; Prati G; Soto Parra HJ; Atzori F; Di Napoli M; Santoni M; Cortellini A; Prati V; Massari F; Sorarù M; Panni S; Fratino L; Sabbatini R; Ricotta R; Boccardo F; Milella M; Procopio G; Zucali PA; et alii...
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis in Frontiers in Oncology
2022
ASL Cuneo 2
Rebuzzi SE; Signori A; Stellato M; Santini D; Maruzzo M; De Giorgi U; Pedrazzoli P; Galli L; Zucali PA; Fantinel E; Carella C; Procopio G; Milella M; Boccardo F; Fratino L; Sabbatini R; Ricotta R; Panni S; Massari F; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra H; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; et alii...
2022
ASL Cuneo 2
Stellato M; Buti S; Maruzzo M; Bersanelli M; Ermacora P; Maiorano BA; Prati V; De Giorgi UFF; Pierantoni F; Malgeri A; Mennitto A; Cavo A; Vitale MG; Santoni M; Carella C; Procopio G; Verzoni E; Santini D;
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis in Frontiers in Oncology
2022
ASL Cuneo 2
Rebuzzi SE; Signori A; Stellato M; Santini D; Maruzzo M; De Giorgi U; Pedrazzoli P; Galli L; Zucali PA; Fantinel E; Carella C; Procopio G; Milella M; Boccardo F; Fratino L; Sabbatini R; Ricotta R; Panni S; Massari F; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra H; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; et alii...
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2021 Feb;14(2):261-268. doi: 10.1080/17512433.2021.1879639. Epub 2021 Jan
2021
ASL Cuneo 2
Procopio G; de Braud FG; Cappelletti V; Guadalupi V; Sepe P; Claps M; Donini M; Ortega C; Atzori F; Morelli F; Bearz A; Miceli R; Chiuri VE; Mosca A; Milella M; Mennitto A; Verzoni E; Cognetti F;
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20
2021
AO Ordine Mauriziano
ASL Cuneo 2
Buti S; Porta C; Perrino M; Brunelli M; Iacovelli R; Paolieri F; Chiellino S; Bersanelli M; Casadei C; Cavo A; Roviello G; Pierantoni F; Prati G; Vignani F; Nolè F; Morelli F; Messina M; Pignata S; Messina C; Stellato M; Atzori F; Soto Parra HJ; Cortellini A; Prati V; Sorarù M; Santoni M; Mollica V; Panni S; Fratino L; et alii...
Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial in Annals of Oncology
2020
ASL Cuneo 2
Verzoni E; Claps M; Apollonio G; Guadalupi V; Montone R; Martinetti A; Sepe P; Mennitto A; Passalacqua R; Donini M; Atzori F; Ortega C; Morelli F; Bearz A; Chiuri VE; Mosca A; Milella M; Miceli R; Cognetti F; Procopio G;
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) in Journal of Clinical Oncology
2020
ASL Cuneo 2
AOU San Luigi di Orbassano
Vitale MG; Zucali PA; Milella M; Santoni M; Procopio G; Ortega C; Naglieri E; Massari F; Fornarini G; Di Lorenzo G; Chiuri VE; Calabro F; Fantinel E; Buttigliero C; Bracarda S; Bonomi L; Bersanelli M; Basso U; Atzori F; Iacovelli R;
Baseline and early change of systemic inflammation index (bSII and ?SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study in Journal of Clinical Oncology
2020
ASL Cuneo 2
Fornarini G; Procopio G; Signori A; Fantinel E; Zucali PA; Paolieri F; Bersanelli M; De Giorgi U; Bimbatti D; Prati V; Roviello G; Soto Parra HJ; Cavo A; Vignani F; Chiellino S; Messina M; Stellato M; Di Napoli M; Atzori F; Rebuzzi SE;
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9.
2019
ASL Cuneo 2
AO Cuneo
Sternberg CN; Caserta C; Cartenì G; Fornarini G; Verusio C; Scoppola A; Crinò L; Frassoldati A; Mini E; Marchetti P; Ortega C; Bidoli P; Ferraù F; Mitterer M; Sabbatini R; Bearz A; Buti S; Basso U; Procopio G; De Giorgi U; Giannarelli D;
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). in Tumori / Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.
2019
ASL Cuneo 2
Cartenì G; Gori S; Nolè F; Pignata S; Conti G; Guida M; Martignoni G; Pappagallo GL; Romano L; Sepe P; Porta C; Procopio G; Ortega C; Passalacqua R; Montironi R; Martorana G; Masini C; Lapini A; Mandressi A; Di Lorenzo G; Cosmai L; Crocetti E; Bracarda S; Vitale MG;
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. in Cancers / Cancers (Basel). 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084.
2019
ASL Cuneo 2
AO Cuneo
Piva F; Cimadamore A; Montironi R; Battelli N; Rizzo M; Merler S; Sorgentoni G; Conti A; Verzoni E; Scagliarini S; Sepe P; Cheng L; Paolucci V; Graham J; Pierce E; Lopez-Beltran A; Atzori F; Scarpelli M; Ortega C; Incorvaia L; Vau N; Iacovelli R; Mosca A; Gelibter A; Carrozza F; Martignetti A; Morelli F; Caffo O; Zucali P; et alii...
Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab in Journal of Clinical Oncology
2019
ASL Cuneo 2
De Giorgi U; Procopio G; Sabbatini R; Caserta C; Mitterer M; Ortega C; Scoppola A; Fornarini G; Ferraú F; Marchetti P; Verusio C; Mini E; Bidoli P; Buti S; Crino L; Basso U; Frassoldati A; Bearz A; Carteni G; Sternberg CN;
Effect of gender on the outcome of patients receiing niolumab for metastatic renal cancer: Results from a large study population in Journal of Clinical Oncology
2019
ASL Cuneo 2
Procopio G; Di Cosimo S; De Giorgi U; Cartenì G; Cortesi E; Caserta C; Sabbatini R; Bearz A; Buti S; Pignata S; Berruti A; Ruggeri E; Bengala C; Livi L; Fagnani D; Bonetti A; Mitterer M; Ortega C; Cognetti F; Di Nicola MA;
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.
2018
ASL Cuneo 2
AOU San Luigi di Orbassano
Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E; Fornarini G; et alii...
A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial in Journal of Clinical Oncology
2018
ASL Cuneo 2
Procopio G; Cognetti F; Miceli R; Milella M; Mosca A; Chiuri VE; Bearz A; Morelli F; Ortega C; Atzori F; Donini M; Ratta R; Martinetti A; Montone R; De Braud FG; Cappelletti V; Verzoni E;
CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology
2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano
Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...
Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): Real world data from an Italian Expanded Access Program (EAP) in Annals of Oncology
2017
ASL Cuneo 2
Procopio G; Prisciandaro M; Iacovelli R; Mancini M; Fornarini G; Facchini G; Cartení G; Napolitano M; Sternberg CN; Caserta C; Bregni M; Massari F; Buti S; Biasco E; De Giorgi U; Zustovich F; Ratta R; Ortega C; Tortora G; Verzoni E;
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents in Oncology (Switzerland)
2017
ASL Cuneo 2
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Porcu L; De Braud F; Porta C; Procopio G;